Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Tana Takacova posted on LinkedIn

Treatment National Cancer Institute

Treatment National Cancer Institute

Therapeutic implications of menin inhibition in acute leukemias

National Cancer Institute (NCI) on LinkedIn: A new type of

Deepanjan Halder on LinkedIn: Revumenib (a Menin inhibitor) shows

Novel menin inhibitors show promise for patients with advanced

Tibsovo Approved for Treatment of Acute Myeloid Leukemia

Clinical Trial Results National Cancer Institute

I-131 apamistamab induces response among adults with advanced

Revumenib: a new therapy for AML patients